@article{7b907dc8d5014c18a13d45d6070b89b0,
title = "Direct and possible indirect effects of vaccination on rotavirus hospitalisations among children in Malawi four years after programmatic introduction",
abstract = "Introduction: Despite increased use of vaccine in routine immunisation, rotavirus remains a major cause of acute gastroenteritis (AGE) in low-income countries. We describe rotavirus prevalence and hospitalisation in Malawi pre and four years post vaccine introduction; provide updated vaccine effectiveness (VE) estimates; and assess rotavirus vaccine indirect effects. Methods: Children under five years of age presenting to a referral hospital in Blantyre with AGE were recruited. Stool samples were tested for rotavirus using Enzyme Immunoassay. The change in rotavirus prevalence was evaluated using Poisson regression. Time series analysis was used to further investigate trends in prevalence over time. VE against rotavirus diarrhoea of any severity was estimated using logistic regression. Indirect effects were estimated by evaluating rotavirus prevalence in unvaccinated children over time, and by comparing observed reductions in incidence of rotavirus hospitalisation to those expected based on vaccine coverage and trial efficacy estimates. Results: 2320 children were included. Prevalence of rotavirus in hospitalised infants (<12 months) with AGE decreased from 69/139(49.64%) prior to vaccine introduction to 197/607(32.45%) post-vaccine introduction (adjusted RR 0.67[95% CI 0.55, 0.82]). Prevalence in children aged 12–23 months demonstrated a less substantial decline: 15/37(40.54%) pre- and 122/352(34.66%) post-vaccine introduction (adjusted RR 0.85, 95% CI 0.57, 1.28). Adjusted VE was 61.89%(95% CI 28.04–79.82), but lower in children aged 12–23 months (31.69% [95% CI −139.03 to 80.48]). In hospitalised infants with rotavirus disease, the observed overall effect of the vaccine was 9% greater than expected according to vaccine coverage and efficacy estimates. Rotavirus prevalence among unvaccinated infants declined post-vaccine introduction (RR 0.70[95% CI 0.55–0.80]). Conclusions: Following rotavirus vaccine introduction in Malawi, prevalence of rotavirus in hospitalised children with AGE has declined significantly, with some evidence of an indirect effect in infants. Despite this, rotavirus remains an important cause of severe diarrhoea in Malawian children, particularly in the second year of life.",
keywords = "Indirect effects, Rotavirus, Vaccines",
author = "{for the VacSurv Consortium} and A. Bennett and L. Pollock and Jere, {K. C.} and Pitzer, {V. E.} and U. Parashar and Tate, {J. E.} and Heyderman, {R. S.} and C. Mwansambo and N. French and O. Nakagomi and M. Iturriza-Gomara and D. Everett and Cunliffe, {N. A.} and N. Bar-Zeev",
note = "Funding Information: This study was supported by the Wellcome Trust [grant numbers 091909/Z/10/Z to NAC and NF and 102466/Z/13/A to AB], the U.S. National Institutes of Health [grant number R01-AI112970 to VEP] and a research grant from GlaxoSmithKline Biologicals to NAC. GlaxoSmithKline Biologicals SA was provided the opportunity to review a preliminary version of this manuscript for factual accuracy but the authors are solely responsible for final content and interpretation. The authors received no financial support or other form of compensation related to the development of the manuscript. Funding Information: NB-Z, K.C.J and NF have received research grant support from GlaxoSmithKline Biologicals for work on rotavirus vaccines. MI-G has received research grant support from GlaxoSmithKline Biologicals and Sanofi Pasteur MSD for work on rotavirus. NAC has received research grant support and honoraria for participation in rotavirus vaccine advisory board meetings from GlaxoSmithKline Biologicals. O. N. has received research grant support and honoraria from Japan Vaccine and MSD for delivering lectures on rotavirus vaccines. Funding Information: The authors thank the collaborating members of the Vaccine Effectiveness and Disease Surveillance Programme, Malawi Consortium (James Beard, Amelia C. Crampin, Carina King, Sonia Lewycka, Hazzie Mvula, Tambosi Phiri, Jennifer R. Verani, and Cynthia G. Whitney) and the VacSurv and RotaRITE study teams. This study was supported by the Wellcome Trust [grant numbers 091909/Z/10/Z to NAC and NF and 102466/Z/13/A to AB], the U.S. National Institutes of Health [grant number R01-AI112970 to VEP] and a research grant from GlaxoSmithKline Biologicals to NAC. GlaxoSmithKline Biologicals SA was provided the opportunity to review a preliminary version of this manuscript for factual accuracy but the authors are solely responsible for final content and interpretation. The authors received no financial support or other form of compensation related to the development of the manuscript. NB-Z, K.C.J and NF have received research grant support from GlaxoSmithKline Biologicals for work on rotavirus vaccines. MI-G has received research grant support from GlaxoSmithKline Biologicals and Sanofi Pasteur MSD for work on rotavirus. NAC has received research grant support and honoraria for participation in rotavirus vaccine advisory board meetings from GlaxoSmithKline Biologicals. O. N. has received research grant support and honoraria from Japan Vaccine and MSD for delivering lectures on rotavirus vaccines. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention (CDC). Publisher Copyright: {\textcopyright} 2018",
year = "2018",
month = nov,
day = "12",
doi = "10.1016/j.vaccine.2018.04.030",
language = "British English",
volume = "36",
pages = "7142--7148",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier Ltd",
number = "47",
}